GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Capex-to-Operating-Cash-Flow

Helix BioPharma (TSX:HBP) Capex-to-Operating-Cash-Flow : 0.00 (As of Jan. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Helix BioPharma's Capital Expenditure for the three months ended in Jan. 2025 was C$0.00 Mil. Its Cash Flow from Operations for the three months ended in Jan. 2025 was C$-0.94 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Helix BioPharma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Helix BioPharma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Capex-to-Operating-Cash-Flow Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Helix BioPharma's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Helix BioPharma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Capex-to-Operating-Cash-Flow falls into.


;
;

Helix BioPharma Capex-to-Operating-Cash-Flow Calculation

Helix BioPharma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jul. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.014) / -5.219
=N/A

Helix BioPharma's Capex-to-Operating-Cash-Flow for the quarter that ended in Jan. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.94
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (TSX:HBP) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Helix BioPharma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.